ERYTECH Presents New Erymethionase Preclinical Findings at the 2019 AACR Annual Meeting

  • Post author:
  • Post category:Newsroom

ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced today the presentation of a poster highlighting new preclinical results for the Company’s second product candidate, erymethionase, at the 2019 American Association of Cancer Research (AACR) annual meeting held in Atlanta, Georgia. The poster (Abstract 2258) is available at